Amoy Diagnostics Co Ltd (300685) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Amoy Diagnostics Co Ltd (300685) has a cash flow conversion efficiency ratio of 0.056x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥110.87 Million ≈ $16.22 Million USD) by net assets (CN¥1.97 Billion ≈ $288.79 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 300685 equity financing ratio to measure how much of total assets are equity-financed.
Amoy Diagnostics Co Ltd - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Amoy Diagnostics Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Amoy Diagnostics Co Ltd (300685) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Amoy Diagnostics Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Amoy Diagnostics Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CHINA RISUN GROUP HD-10
F:45Y
|
N/A |
|
Ningbo Fujia Industrial Co Ltd
SHG:603219
|
0.020x |
|
Elco Ltd
TA:ELCO
|
-0.042x |
|
Thinking Electronic Industrial Co Ltd
TW:2428
|
0.046x |
|
MidWestOne Financial Group Inc
NASDAQ:MOFG
|
0.029x |
|
Guangdong Hoshion Aluminium Co Ltd
SHE:002824
|
0.069x |
|
Invisio Communications AB
ST:IVSO
|
0.047x |
|
Elopak AS
OL:ELO
|
0.054x |
Annual Cash Flow Conversion Efficiency for Amoy Diagnostics Co Ltd (2012–2024)
The table below shows the annual cash flow conversion efficiency of Amoy Diagnostics Co Ltd from 2012 to 2024. For the full company profile with market capitalisation and key ratios, see Amoy Diagnostics Co Ltd market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥1.84 Billion ≈ $269.73 Million |
CN¥341.85 Million ≈ $50.02 Million |
0.185x | +5.75% |
| 2023-12-31 | CN¥1.70 Billion ≈ $249.25 Million |
CN¥298.72 Million ≈ $43.71 Million |
0.175x | +76.47% |
| 2022-12-31 | CN¥1.50 Billion ≈ $219.46 Million |
CN¥149.04 Million ≈ $21.81 Million |
0.099x | -19.06% |
| 2021-12-31 | CN¥1.37 Billion ≈ $200.42 Million |
CN¥168.16 Million ≈ $24.61 Million |
0.123x | -37.22% |
| 2020-12-31 | CN¥1.13 Billion ≈ $165.13 Million |
CN¥220.69 Million ≈ $32.29 Million |
0.196x | +16.43% |
| 2019-12-31 | CN¥902.11 Million ≈ $132.01 Million |
CN¥151.52 Million ≈ $22.17 Million |
0.168x | +36.02% |
| 2018-12-31 | CN¥756.74 Million ≈ $110.73 Million |
CN¥93.45 Million ≈ $13.67 Million |
0.123x | -12.76% |
| 2017-12-31 | CN¥649.20 Million ≈ $95.00 Million |
CN¥91.89 Million ≈ $13.45 Million |
0.142x | +35.41% |
| 2016-12-31 | CN¥307.91 Million ≈ $45.06 Million |
CN¥32.18 Million ≈ $4.71 Million |
0.105x | +35.70% |
| 2015-12-31 | CN¥247.90 Million ≈ $36.28 Million |
CN¥19.10 Million ≈ $2.79 Million |
0.077x | -57.03% |
| 2014-12-31 | CN¥87.54 Million ≈ $12.81 Million |
CN¥15.69 Million ≈ $2.30 Million |
0.179x | -17.67% |
| 2013-12-31 | CN¥39.30 Million ≈ $5.75 Million |
CN¥8.56 Million ≈ $1.25 Million |
0.218x | +1888.50% |
| 2012-12-31 | CN¥17.25 Million ≈ $2.52 Million |
CN¥-210.00K ≈ $-30.73K |
-0.012x | -- |
About Amoy Diagnostics Co Ltd
Amoy Diagnostics Co., Ltd. engages in research and development, production, sale, and supporting services of tumor precision medical diagnostic products in China and internationally. The company offers AmoyDx homologous recombination deficiency (HRD) focus panel solutions, evaluates PARP inhibitor-related biomarkers and advances targeted treatment research in ovarian cancer; AmoyDx comprehensive … Read more